Latest KRAS Stories
Doctors and researchers of Hospital del Mar and its research institute, the IMIM, have lead a study describing a new pharmacological resistance to cancer.
Until now, researchers have not examined never-smokers as extensively as they have smokers as potential lung cancer patients.
The investigational drug ganetespib, a synthetic second-generation Hsp90 inhibitor, slowed the growth of cancer cells taken from non-small cell lung cancer tumors with a mutation in the KRAS gene.
Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but survival rates were reportedly "unsatisfactory."
Multicentric carcinogenesis with the same genetic mutation appears to occur in lung adenocarcinoma.
Smoking is a well-known risk factor for lung cancer, but about 25% of all lung cancer patients have never smoked. According to this study, a gene fusion event could explain a significant proportion of these lung cancer cases, and may serve as a target for new therapies.
Smoking is a well-known risk factor for lung cancer, but nearly 25% of all lung cancer patients have never smoked.
Yale Cancer Center researchers have shown that a tiny genetic variation predicts chances of survival and response to treatment for patients with ovarian cancer.
- In dressmaking, straps running from the belt in front over the shoulders to the belt in the back, with more or less elaboration of trimming and outline. They usually broaden at the shoulder and narrow toward the waist.